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Abstract
There are conflicting ideas regarding the location of the carboxyl-terminal regions of cross-linked γ-chain
dimers in double-stranded fibrin fibrils. Some investigators believe that the chains are always oriented
longitudinally along each fibril strand and traverse the contacting ends of abutting fibrin D domains
(“DD-long” cross-linking). Other investigations have indicated instead that the chains are situated
transversely between adjacent D domains in opposing fibril strands (transverse cross-linking). To
distinguish between these two possibilities, the γ dimer composition of factor XIIIa-cross-linked
fibrin/fibrinogen complexes that had been formed through noncovalent D/E interactions between
fibrinogen D domains and fibrin E domains was examined. Two factor XIIIa-mediated cross-linking
conditions were employed. In the first, fibrin/fibrinogen complexes were formed between 125I-labeled
fibrinogen 2 (“peak 2” fibrinogen), each heterodimeric molecule containing one γA and one larger γ‘
chain, and nonlabeled fibrin 1 molecules (“peak 1” fibrin), each containing two γA chains. If DD-long
cross-linking occurred, 125I-labeled γA−γA, γA−γ‘, and γ‘−γ‘dimers in a 1:2:1 ratio would result. Transverse
cross-linking would yield a 1:1 mixture of 125I-labeled γA−γA and γA−γ‘ dimers, without any γ‘−γ‘ dimers.
Autoradiographic analyses of reduced SDS−PAGE gels from protocol 1 revealed 125I-labeled γA−γA and
γA−γ‘ dimers at a ratio of ∼1:1. No labeled γ‘−γ‘ dimers were detected. Protocol 2 used a converse
mixture, 125I-fibrin 2 and nonlabeled fibrinogen 1. DD-long cross-linking of this mixture would yield only
nonradioactive γA−γA dimers, whereas transverse cross-linking would yield a 1:1 mixture of 125I-labeled
γA−γA and γA−γ‘ dimers. Autoradiographic analyses of this mixture yielded 125I-labeled γA−γA and γA−γ‘
dimers in a 1:1 ratio. These findings provide no evidence that longitudinal (DD-long) γ chain positioning
occurs in cross-linked fibrin and indicate instead that most, if not all, γ-chain positioning in an assembled
fibrin polymer is transverse.

Following thrombin-catalyzed conversion of fibrinogen to fibrin, polymer assembly commences with
noncovalent intermolecular interactions between the D domains and the E domains of neighboring
molecules (1−6), resulting in double-stranded fibrils composed of a half-staggered overlapping array of
molecules (7−13). In the presence of factor XIIIa, fibrin assembly is accompanied by intermolecular
covalent cross-linking, in which ε-amino-(γ-glutamyl)lysine isopeptide bonds are introduced between
appropriately positioned donor lysine and acceptor glutamine residues (14, 15). Cross-linking occurs
rapidly between γ chains, forming γ dimers, more slowly between α chains to form α polymers (16, 17),
and between α and γ chains (18−21).
Positioning of D domains in the fibrin polymer facilitates intermolecular covalent cross-linking between γ
chains, resulting in reciprocal isopeptide bonds between paired donor−acceptor sites in the carboxyterminal regions of γ chains (22−25). The orientation of the carboxy-terminal γ-chain dimers in crosslinked fibrin fibers remains in dispute. Several investigators have suggested that the chains are oriented
longitudinally, parallel to each fibril strand, traversing the contacting ends of abutting fibrin D domains
in a so-called DD-long arrangement (11, 26−28). This model draws support from ultrastructural studies
of factor XIIIa-cross-linked fibrinogen molecules that showed dimeric structures aligned end-to-end (11,
26, 27), from studies of the morphology of plasmin degradation products of cross-linked fibrin (28), and
from the appearance of fibrinogen molecules organized on a fibrin fragment E template (29). This model
has also gained support from analyses of D-domain crystal structure, since theoretical calculations of

carboxy-terminal γ chain lengths suggested that only DD-long positioning was possible in such structures
(30, 31).
Other investigations have indicated that γ dimers are situated between D domains on opposite strands
of the double-stranded fibrin fibrils (18, 32−36), in a transverse arrangement (DD-trans). This crosslinking pattern was first proposed by Selmayr et al. (32), who found that, in the presence of factor XIIIa,
fibrinogen formed a covalently cross-linked complex with immobilized fibrin, an arrangement that could
only have come about through transverse orientation of γ-chain cross-links. In later electron microscopic
studies (33) they showed that cross-linked double-stranded fibrin fibrils were not depolymerized by 3 M
urea, a solvent that disrupted noncovalent D/E interactions, thus reinforcing their conclusion that crosslinked γ chains were positioned transversely. Ultrastructural analyses of cross-linked fibrinogen
polymers demonstrated double-stranded fibrils that had formed through cross-linked γ chains that
traversed the strands (34), allowing the extrapolation that this situation holds for fibrin as well. More
recently, high-resolution electron microscopic visualization of gold cadaverine-labeled γ chains in
fibrinogen and fibrin molecules has shown that the C-terminal regions are most often oriented toward
the central domain of the molecule, suitably aligned for transverse cross-linking (36). Even better
evidence for transverse cross-link orientation comes from a biochemical study demonstrating that
mixtures of fibrin and plasmic fragment D produced primarily covalently cross-linked D/fibrin/D
complexes in the presence of factor XIIIa (35).
Human fibrinogen can be separated into two major chromatographic fractions, fibrinogen 1 (“peak 1”
fibrinogen) and fibrinogen 2 (“peak 2” fibrinogen) (37, 38). The two fibrinogens differ from each other
with respect to their γ-chain compositions. Fibrinogen 1 contains two γA chains, whereas heterodimeric
fibrinogen 2 molecules each contain one γA and one γ‘ chain. Factor XIIIa-treated mixtures of
radioactively labeled fibrinogen 2 and fibrin 1 or radioactively labeled fibrin 2 and fibrinogen 1 will
produce distinguishable combinations of radioactive γ-chain dimers depending upon whether crosslinking occurs in the DD-long or in the transverse orientation. By analyzing the γ dimer population in
mixtures of 125I-labeled fibrinogen 2 and fibrin 1 or 125I-labeled fibrin 2 and fibrinogen 1, this situation
was exploited to show that transverse cross-linking occurs in fibrinogen/fibrin complexes and
underscores the conclusion that cross-linked γ chains are positioned transversely in an assembled fibrin
polymer.

Materials and Methods
Tris, 1 glycine, Coomassie Brilliant Blue R250, and DTT were purchased from Aldrich Chemical Co.,
Milwaukee, WI. Trasylol (aprotinin) was obtained from Miles Inc., Kankakee, IL, and DE-52 cellulose was
from Whatman Inc., Clifton, NJ. Human α-thrombin (3188 units/mg) was obtained from Enzyme
Research Laboratories, South Bend, IN. Other chemicals were the highest purity available from
commercial sources.
Human fibrinogen was isolated from pooled citrated plasma by glycine precipitation (39), further
purified as previously described (40), and then subfractionated into fibrinogen 1 (γA−γA) and fibrinogen 2
(γA−γ‘) by chromatography on DE-52 (41). Normal fibrinogen contains small amounts of an
intramolecular cross-linked α−γ chain that migrates on reduced SDS−PAGE near the γA−γ‘ dimer position
(42). Radioactively labeled fibrinogen containing the α−γ dimer can obscure γA−γ‘ quantification. This
small fraction was removed from the fibrinogen preparations either by precipitating the fibrinogen 2

preparations with 20% ammonium sulfate (43) or by preparing I-9 fibrinogen 2 (40), which is devoid of
α−γ dimer.
Fibrinogen 2 that was devoid of the α∠γ dimer was labeled with 125I by the iodine monochloride method
(44), resulting in a labeling ratio of 2 atoms of 125I per fibrinogen molecule. Soluble fibrin 1 monomer
and 125I labeled I-9 fibrin 2 monomer (≥10 mg/mL in 20 mM acetic acid) were prepared by the method of
Belitser et al. (45). Fibrinogen and soluble fibrin concentrations were determined
spectrophotometrically at 280 nm using an absorbance coefficient (𝐴𝐴1%
cm ) of 15.1 (46).
Factor XIII was purified from pooled human plasma (47) and assayed by the method of Loewy et al. (48).
The specific activity of the preparation was 2000 Loewy units/mg. Human plasma contains up to 120
Loewy units of factor XIII/mL. Factor XIII was activated to factor XIIIa by incubation with thrombin (10
units/mL) (49) for 30 min at 37 °C and the thrombin then inactivated by incubating with a 5-fold excess
of hirudin (50 units/mL) (34).
Fibrinogen:fibrin ratios ranging from 2:1 to 15:1 at a final protein concentration of 1 mg/mL and factor
XIIIa levels ranging from 5 to 100 Loewy units/mL were evaluated to determine the optimal conditions
for fibrin/fibrinogen γ-chain dimer cross-linking. Cross-linking of experimental mixtures was initiated by
adding factor XIIIa and incubating at 37 °C. The cross-linking reaction was terminated at 5-min intervals
by adding an equal volume of double-strength Laemmli sample buffer containing 1% βmercaptoethanol. The samples were analyzed by reduced SDS−PAGE. It was determined that a
fibrinogen:fibrin ratio of 8:1 or higher yielded completely solubilized fibrin and that a factor XIIIa level of
20 Loewy units/mL permitted incubations of up to 15 min before significant fibrinogen−fibrinogen γchain cross-linking became evident.
Fibrin/fibrinogen reaction mixtures for protocol 1 were prepared by mixing fibrin 1 monomer solutions
with 125I-fibrinogen 2 in a buffer of 50 mM Tris, 100 mM NaCl, 10 mM CaCl2, and 0.2 mM PMSF, pH 7.4.
For protocol 2, 125I-labeled I-9 fibrin 2 monomer solutions were mixed with fibrinogen 1 in a buffer of 50
mM Tris, 100 mM NaCl, 10 mM CaCl2, and 0.2 mM PMSF, pH 7.4. In both instances the ratio of
fibrinogen to fibrin was 8:1 at a final protein concentration of 1 mg/mL, the factor XIIIa level was 20
Loewy units/mL, and the mixtures were incubated at 37 °C. Samples were taken at 5, 10, or 15 min as
described above. Control fibrinogen/fibrinogen mixtures contained fibrinogen 1 and 125I-fibrinogen 2 at
the same molar ratios and were treated with factor XIIIa under the identical conditions.
The products of the cross-linking reaction were analyzed by SDS−PAGE employing the discontinuous
buffer system of Laemmli (50) on 9% polyacrylamide gels. Gels were stained with 0.5% Coomassie
Brilliant Blue R250 in methanol/water/acetic acid (5:5:1), destained in methanol/water/acetic acid
(5:5:1) with continuous shaking, and dried. Dried gels were subjected to autoradiography for up to 15
days with Kodak X-Omat X-ray film.
To evaluate how much of the available fibrin had been utilized during the cross-linking reaction,
mixtures of reduced cross-linked fibrin 2 and fibrinogen 1 were prepared with fibrinogen:fibrin ratios
ranging from 4:1 to 32:1. These mixtures were then subjected to reduced SDS−PAGE as described above,
and the gels were stained with Coomassie Brilliant Blue. Stained gels were digitized on a UMAX Astra
2400S flat-bed scanner (UMAX Technologies, Fremont, CA), and bands in the γ dimer position (γA−γA,
γA−γ‘, and γ‘−γ‘) and Bβ-chain regions of the gel were quantified by use of NIH Image (v1.62). A
calibration curve was constructed by plotting the fibrinogen:fibrin ratio against the amount of protein in

the γ dimer region normalized against the Bβ-chain region. Based upon this calibration curve, if all the
fibrin in the experimental mixtures became incorporated into cross-linked complexes, 18% of the total
protein would be found in the γ dimer region. This amount of the total protein is defined as the
theoretical maximum amount of γ dimers. Stained experimental gels were digitized and the calibration
curve was used to determine the amount of available fibrin that had undergone cross-linking. The
amount of protein found in the γ dimer region of the control and experimental gels is reported as a
percentage of this theoretical maximum amount, i.e., (amount in control or experimental samples ÷
theoretical maximum) × 100. Autoradiographs of the experimental samples were likewise digitized and
the ratio of γA−γA, γA−γ‘, and γ‘−γ‘ dimers in these samples was calculated from these images.

Results
The rationale for the cross-linking experiments employing radioactive fibrinogen/fibrin mixtures is
depicted in Figures 1 and 2. D domains from two fibrinogen molecules bind noncovalently to the
available complementary polymerization sites in the fibrin E domain (D/E) to form a trimolecular
complex. In the presence of factor XIIIa, covalent cross-links are introduced between the carboxyterminal regions of two appropriately positioned γ chains. γA and γ‘ chains are easily distinguishable by
differences in their sizes, but they undergo cross-linking with one another nonselectively (51). When the
fibrinogen/fibrin mixture consists of 125I-labeled fibrinogen 2 (γA, γ‘) and fibrin 1 (γA, γA) (protocol 1), DDlong cross-linking would yield 125I-labeled γA−γA, γA−γ‘, and γ‘−γ‘ dimers in a 1:2:1 ratio. Transverse crosslinking of this same mixture would result in 125I-labeled γA−γA and γA−γ‘ dimers in a 1:1 ratio; γ‘−γ‘ dimers
would not form. Alternatively, when the fibrinogen/fibrin mixture consists of 125I-fibrin 2 and fibrinogen
1 (protocol 2), DD-long cross-linking would yield only nonradioactive γA−γA dimers, whereas transverse
cross-linking would yield 125I-labeled γA−γA and γA−γ‘ dimers at a 1:1 ratio.

Figure 1 Diagrammatic representation of protocol 1, in which 125I-fibrinogen 2 (γA, γ‘) and fibrin 1 (γA, γA)
are incubated with factor XIIIa. The outcome of DD-long cross-linking versus transverse cross-linking is
depicted in terms of γ dimer formation.

Figure 2 Diagrammatic representation of protocol 2 in which 125I-fibrin 2 (γA, γ‘) and fibrinogen 1 (γA, γA)
are incubated with factor XIIIa. The outcome of DD-long cross-linking versus transverse cross-linking is
depicted in terms of γ dimer formation.
When mixtures of 125I-labeled fibrinogen 2 (γA, γ‘) and fibrin 1 (γA, γA) were cross-linked by factor XIIIa
(protocol 1, Figure 3), two γ dimer bands migrating in the γA−γA and γA−γ‘ positions were present by the
5-min sample. The γA−γA band contained 44% of the protein in the γ dimer region of the gel, and the
γA−γ‘ band contained 56% (mean of three trials). No band was ever detected in the γ‘−γ‘ region of the
gel. Based upon scans of the stained gels, 25% of the possible fibrin/fibrinogen cross-linked dimers were
in the γ dimer region of the gel. Few, if any, γ dimers were present in the 5 min fibrinogen 2/fibrinogen 1
control sample. As the time of incubation increased, the intensity of the two γ dimer bands increased in
the experimental sample. At the 15 min time point, 67% of the possible fibrin/fibrinogen cross-linked
dimers were present in the γ dimer region (mean of three trials). The γA−γA band contained 49% of the
protein in the γ dimer region and the γA−γ‘ band contained 51%, a 1:1 molar ratio. A γ‘−γ‘ dimer band
was never detected. In the 15 min fibrinogen/fibrinogen control sample, small amounts of γ dimers
were found. Compared to the fibrin/fibrinogen mixtures, the γ dimers present in the control sample
amounted to 8% of the theoretically possible amount of γ dimers. This low level of γ dimers in the
control sample was no doubt due to cross-linking among non-fibrin-complexed fibrinogen molecules.
Overall, the results are consistent only with transverse positioning of γ chains.

Figure 3 Autoradiograph of a mixture of 125I-fibrinogen 2 (γA, γ‘) and fibrin 1 (γA, γA) that had been
incubated with factor XIIIa. 125I-Fibrinogen 2 and fibrin 1 at an 8:1 molar ratio were incubated with factor
XIIIa (20 units/mL) at 37 °C for the indicated times. A control sample consisted of 125I-fibrinogen 2 and
fibrinogen 1 incubated at the same molar ratio of 8:1 in the presence of factor XIIIa. The positions of the
γA−γA, γA−γ‘, and γ‘−γ‘ dimer bands were assigned by reference to a marker lane containing crosslinked 125I-fibrin 2. The bands in the marker lane that was included in this run were readable and usable
but unsightly. Accordingly, the marker lane from another gel run, which had been run under the same
conditions, has been substituted. C, control sample; E, experimental sample; XL, cross-linked 125I-labeled
I-9 fibrin 2.
In the converse experiment, autoradiographs of 125I-labeled I-9 fibrin 2 and fibrinogen 1 cross-linking
mixtures revealed at the 5-min time point γ dimer bands migrating in the γA−γA and γA−γ‘ positions
(protocol 2, Figure 4), amounting to 17% of the possible fibrin/fibrinogen cross-linked dimers (mean of
three trials). Cross-linking among 125I-fibrin 2 molecules did not occur under these conditions because no
γ‘−γ‘ dimer band was evident at any time. As the incubation time increased, the intensity of the γ dimer
bands increased. At 15 min the γ dimer region contained 74% of the theoretically possible
fibrin/fibrinogen γ dimers. The γA−γA band accounted for 52% of the protein and the γA−γ‘ area
contained 48%, a 1:1 ratio (mean of three trials). In the fibrinogen/fibrinogen controls, radioactive γ
dimers did not become apparent until the 15 min time point. Compared to the fibrin/fibrinogen
mixtures, the γ dimers in this control sample amounted to only 14% of the possible fibrin/fibrinogen
dimers. Radioactive γ dimer bands above the levels observed in controls could have formed only if γchain cross-linking had occurred from a transverse orientation.

Figure 4 Autoradiograph of a mixture of 125I-fibrin 2 and fibrinogen 1 (γA, γA) that had been incubated
with factor XIIIa. Fibrinogen 1 and 125I-fibrin 2 at an 8:1 molar ratio were incubated with factor XIIIa (20
units/mL) at 37 °C for the indicated times. A control sample consisted of 125I-fibrinogen 2 and fibrinogen
1 incubated at the same molar ratio of 8:1 in the presence of factor XIIIa. The low level of radioactivity in
the intact α chain position is due to the fact that intact α chains are absent in the fraction I-9 fibrinogen
2 that was used. The positions of the γA−γA, γA−γ‘, and γ‘−γ‘ dimer bands were assigned by reference to a
marker lane containing cross-linked 125I-fibrin 2. C, control sample; E, experimental sample; XL, crosslinked 125I labeled I-9 fibrin 2.

Discussion
An earlier study that was concerned with the question of γ-chain orientation employed mixtures of
fibrin and plasmic fragment D to probe the orientation of fibrin γ chains (35) and was conceptually
similar to the one presented here. Those findings led to the same conclusion as ours with regard to γchain orientation in fibrin. Coupled with other previous (18, 32−34) and subsequently published
experiments (36), we ingenuously were led to believe that further experiments along these lines would
not be necessary. That seems not to be the case, judging from conclusions drawn in recent publications
concerned with the structure of fibrinogen molecules organized on a fragment E template (29) and the
interpretations based upon X-ray crystallographic studies of the fibrin D domain (30, 31).
Conclusions regarding γ-chain orientation in fibrin based upon crystallographic analyses are worthy of
comment. Based upon calculations of the length of the exposed carboxyl-terminal regions of the γ
chains and the distance required to bridge the span between the D domains, Yee et al. (30) suggested
that transverse cross-linking would be unlikely. Spraggon et al. (31) used similar logic based on their
observations of a cross-linked fibrin D dimer fragment. Although they were unable to visualize the
position of the cross-linked γ chains, they could easily surmise the general location of the cross-linked γ
chains in the fragment. From this they evidently extended their reasoning to conclude that cross-linking
in fibrin must occur in a DD-long orientation. Although crystallographic studies provide many important

details on the folding and conformation of the fibrinogen D domain, it must be recognized that for a
variety of reasons the configuration and conformation of a structure in the crystalline state may differ
significantly from that of the native molecule in solution. For example, in the crystal structure of the γ
module the sequence γ381−390, which directly leads to the terminal cross-linking site of the γ chain, is
inserted as the middle strand of a five-stranded antiparallel β sheet. Medved et al. (52) have shown that
this strand can be removed from its insertion in the γ module without disrupting the compact structure
of the module. This implies that the carboxyl-terminal cross-linking region can in turn become
considerably more extended than it is in the crystal structure.
The different γ-chain compositions of fibrinogen 1 (γA, γA) and fibrinogen 2 (γA, γ‘) (37, 38) provided a
means for distinguishing between the DD-long and transverse γ-chain cross-linking arrangements.
Analysis of the γ-chain dimers formed in cross-linking mixtures of fibrin 1 and 125I-fibrinogen 2
yielded 125I-labeled γA−γA and γA−γ‘ dimers accounting for 67% of the total possible fibrin/fibrinogen γchain dimers before the appearance of significant fibrinogen/fibrinogen dimers. Mixtures of 125I-fibrin 2
and fibrinogen 1 also yielded 125I-labeled γA−γA and γA−γ‘ dimers, accounting for 74% of the total possible
fibrin/fibrinogen γ-chain dimers. This combination of γ dimers under both experimental conditions could
only have resulted from cross-linking in the transverse orientation. The paucity of cross-linked γ-chain
dimers in control fibrinogen/fibrinogen mixtures indicates that, under the conditions employed, factor
XIIIa preferentially cross-linked assembled fibrinogen/fibrin complexes. This is expected since it is wellknown that fibrinogen γ chains become cross-linked more slowly than do fibrin γ chains (34,49). While
not eliminating the possibility of a DD-long orientation of γ chains under certain defined circumstances,
such as in D dimer fragments, these experiments, in addition to a substantial body of existing data,
strongly indicate that transverse positioning of γ chains occurs in fibrinogen/fibrin complexes and that
cross-linked γ chains are oriented in the same manner in assembled fibrin.
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